Europe Rapid Diagnostic Test (RDT) Market, By Product Type (Consumables and Kits, Instruments, and Others), Mode (Professional and Over-The-Counter [OTC]), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology, and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum, and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, and Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2031.
Europe Rapid Diagnostic Tests (RDT) Market Analysis and Insights
Rise in rapid diagnostic tests for the diagnosis of chronic infectious diseases such as Human Immuno Deficiency Virus (HIV), malaria, and other diseases are driving the market growth. Lack of skilled professionals has caused many accidents and errors during diagnostics is expected to challenge market growth.
Data Bridge Market Research analyses that the Europe Rapid Diagnostic Tests (RDT) market is expected to reach USD 21.64 billion by 2031 from USD 12.05 billion in 2023, growing with a healthy CAGR of 8.2% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product Type (Consumables and Kits, Instruments, and Others), Mode (Professional and Over-The-Counter [OTC]), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology, and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum, and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, and Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe
|
|
Market Players Covered
|
Abbott, Danaher, Cellex, Fujirebio, AdvaCare Pharma, ACCESS BIO, Cardinal Health, Bio-Rad Laboratories, Inc., Cepheid, BD, F. Hoffmann-La Roche Ltd, bioMérieux SA, InBios International, Inc, Luminex Corporation, Gnomegen LLC, QIAGEN, Quidel Corporation, , Inc., Sysmex Corporation, Cardinal Health, Siemens Healthcare Gmbh, MEGACOR DIAGNOSTIK, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics, werfen, Nova Biomedical, and Trinity Biotech among others
|
Market Definition
Rapid diagnostic tests are preferred over standard diagnostic tests since they can boost the aetiologic analysis of infections in several situations (for instance, sepsis, respiratory tract infections, and meningitis). The elucidation of the currently available rapid diagnostic tests is not always upfront, and therefore, they cannot yet replace conventional tests. There are three types of rapid diagnostic tests. The rapid immunoassay test strips or cassettes are used to measure the concentration of a chemical. Test strips are most often used to test the pH level of a liquid in a sample, but some types of test strips serve other purposes, such as detecting the presence of a contaminant.
Europe Rapid Diagnostic Tests (RDT) Market Dynamics
Drivers
- Increase in the Incidence of Chronic Diseases
The driving factors responsible for the growth of the market is the increase in the incidence of chronic diseases, the rise in the geriatric population, technological developments in rapid diagnostic tests, and the rise in product launches. However, the factors that are expected to restrain the market are the rise in the cost of rapid diagnostics, product recalls faced in rapid diagnostic tests, and lack of awareness about the use of rapid diagnostics. Moreover, the strategic initiatives by market players and the rise in healthcare expenditure bolster the market growth.
- Rise in Geriatric Population of the Infectious Diseases
The aging population worldwide is facing an increased risk of chronic and malignant diseases due to a variety of factors, including changes in the immune system, lifestyle, and exposure to environmental factors over time. The susceptibility of the geriatric population to such health challenges highlights the importance of effective and efficient diagnostic tools to identify and manage these conditions. One notable aspect in this context is the prevalence of non-specific antibodies in the elderly, making the detection of specific diseases more challenging.
Opportunity
- Strategic Initiation and Product Launches by Market Players
The market is experiencing a notable trend marked by a rising initiation of new products and launches. This surge in innovation underscores the dynamic nature of the diagnostic landscape, with companies actively introducing novel solutions to address evolving healthcare needs. The growing demand for accurate and rapid diagnostic tools, particularly in the context of an aging population, has stimulated increased investment in research and development.
Restraints/Challenges
- High Cost Associated with the Rapid Diagnostic Kits
The rise in the cost of the rapid diagnostic kit due to robust research and effectiveness. However, the price of the material used and the developments incurred in the therapeutics and services would increase the number of manufacturing units and more workforce and human resources required to diagnose and screen pathogen viability.
The rapid diagnostic development cost is expensive, it requires a proper protocol procurement strategy. However, specialty clinics and diagnostic laboratories face hindrances in purchasing testing devices due to low economic financials, which would limit the sales of test kits and their accessories.
- Stringent Regulations for Market Approval
The regulations are provided for all aspects of the rapid diagnostics tests, such as In-vitro and molecular diagnostics. These rules and regulations are required for market approval to ensure the security and safety of the patients.
Achieving these regulatory approvals for legal formality can entail significant financial expenditure, which could take months or years to complete. If these limitations are not known or taken into account, the probability of success in a highly competitive market can be significantly exposed by delays, which is expected to challenge market growth.
Recent Developments
- In May 2023, F. HOFFMANN-LA ROCHE LTD officially announced the acquisition of Stratos Genomics. This acquisition led to the development of DNA-based sequencing for diagnostics use. This enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company
- In April 2023, In July, bioMérieux SA’s BIOFIRE Respiratory Panel 2.1 plus tests for 23 pathogens, including SARS-CoV-,2 infection, responsible for respiratory tract infections is commercially available for use around the world and helps in the early diagnosis of respiratory infections. This development assisted the company in generating more revenue
Europe Rapid Diagnostic Tests (RDT) Market Scope
The Europe Rapid Diagnostic Tests (RDT) market is categorized into eleven notable segments based on product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables and Kits
- Others
On the basis of product type, the market is segmented into consumables and kits, instruments, and others.
Mode
- Over-The-Counter [OTC]
- Professional
On the basis of mode, the market is segmented into professional and Over-The-Counter [OTC].
Technology
- PCR-Based
- Flow-Through Assays
- Lateral Flow Immunochromatographic Assays
- Microfluidics
- Substrate Technology
- Agglutination Assay
- Others
On the basis of technology, the market is segmented into PCR-based, flow-through assays, lateral flow immunochromatographic assays, agglutination assay, microfluidics, substrate technology, and others.
Modality
- Laboratory Based Test
- Non-Laboratory Based Test
On the basis of modality, the market is segmented into laboratory based test and non-laboratory based test.
Age Group
- Pediatric
- Adult
On the basis of age group, the market is segmented into adult and pediatric.
Test Type
- Determining Confirmation
- Serological Testing
- Viral Sequencing
On the basis of test type, the market is segmented into determining confirmation, serological testing, and viral sequencing.
Approach
- Molecular Diagnostic
- In-Vitro Diagnostic
On the basis of approach, the market is segmented into in-vitro diagnostic and molecular diagnostic.
Specimen
- Swab
- Blood
- Urine
- Saliva
- Sputum
- Others
On the basis of specimen, the market is segmented into swab, blood, urine, saliva, sputum, and others.
Application
- Infectious Disease Testing
- Cardiology Testing
- Oncology Testing
- Pregnancy & Fertility Testing
- Toxicology Testing
- Drugs-of-Abuse Testing
- Cardiometabolic Testing
- Glucose Monitoring
- Others
On the basis of application, the market is segmented into infectious disease testing, glucose monitoring, cardiology testing, oncology testing, cardiometabolic testing, drugs-of-abuse testing, pregnancy & fertility testing, toxicology testing, and others.
End User
- Hospital & Clinic
- Diagnostic Laboratory
- Home Care Setting
- Research and Academic Institutes
- Others
On the basis of end user, the market is segmented into hospital & clinic, diagnostic laboratory, home care setting, research and academic institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Regional Analysis: Europe Rapid Diagnostic Tests (RDT) Market
The Europe Rapid Diagnostic Tests (RDT) market is analyzed and market size information is provided product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel.
The countries covered in the Europe Rapid Diagnostic Tests (RDT) market report are the Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and rest of Europe.
Germany is expected to dominate in the market due to the presence of major market players and increased technological advancements of Europe rapid diagnostic test in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Europe Rapid Diagnostic Tests (RDT) Market: Competitive Landscape and Share Analysis
Europe Rapid Diagnostic Tests (RDT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Europe rapid diagnostic test market.
The major companies providing the Europe Rapid Diagnostic Tests (RDT) market are Abbott, Danaher, Cellex, Fujirebio, Pharma, Access Bio, Cardinal Health, Bio-Rad Laboratories, Inc., BD, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX SA, InBios International, Inc, Luminex Corporation. A DiaSorin Company, Gnomegen LLC, QIAGEN, Quidel Corporation, Sysmex Europe Gmbh (A Subsidiary of Sysmex Corporation), Cardinal Health, Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG), MEGACOR DIAGNOSTIK GMBH, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics, werfen, Nova Biomedical, and Trinity Biotech among others.
SKU-